Controlling Rotavirus-associated diarrhea: Could single-domain antibody fragments make the difference?  by Maffey, Lucia et al.
RS
C
C
m
L
I
R
A
h
0
Bev Argent Microbiol. 2015;47(4):368--379
www.elsevier.es/ram
R  E  V  I  S  T  A  A  R  G  E  N  T  I  N  A  D  E
MICROBIOLOGÍA
PECIAL ARTICLE
ontrolling  Rotavirus-associated  diarrhea:
ould single-domain  antibody  fragments
ake the  difference?
ucia Maffey, Celina G. Vega, Viviana Parren˜o ∗, Lorena Garaicoechea
nstituto  de  Virología,  Centro  de  Investigaciones  en  Ciencias  Veterinarias  y  Agronómicas,  INTA  Castelar,  Buenos  Aires,  Argentina
eceived 3  June  2015;  accepted  21  September  2015
vailable  online  1  December  2015
KEYWORDS
Rotavirus;
Neonatal  diarrhea;
VHHs;
Single  domain
antibody  fragments;
Nanobodies
Abstract  Group  A  Rotavirus  (RVA)  remains  a  leading  cause  of  severe  diarrhea  and  child  mortal-
ity. The  variable  domain  of  camelid  heavy  chain  antibodies  (VHH)  display  potent  antigen-binding
capacity,  have  low  production  costs  and  are  suitable  for  oral  therapies.  Two  sets  of  anti-RVA
VHHs have  been  developed:  ARP1-ARP3;  2KD1-3B2.  Here,  we  explore  the  potential  of  both
sets as  a  prevention  strategy  complementary  to  vaccination  and  a  treatment  option  against
RVA-associated  diarrhea  in  endangered  populations.  Both  sets  have  been  expressed  in  multiple
production  systems,  showing  extensive  neutralizing  capacity  against  strains  of  RVA  in  vitro.  They
were also  tested  in  the  neonatal  mouse  model  with  various  degrees  of  success  in  preventing
or treating  RVA-induced  diarrhea.  Interestingly,  mitigation  of  the  symptoms  was  also  achieved
with freeze-dried  ARP1,  so  that  it  could  be  applied  in  areas  where  cold  chains  are  difﬁcult  to
maintain. 3B2  was  tested  in  a  pre-clinical  trial  involving  gnotobiotic  piglets  where  it  conferred
complete  protection  against  RVA-induced  diarrhea.  ARP1  was  used  in  the  ﬁrst  clinical  trial  for
anti-RVA VHHs,  successfully  reducing  stool  output  in  infants  with  RVA  diarrhea,  with  no  detected
side effects.
©  2015  Asociación  Argentina  de  Microbiología.  Published  by  Elsevier  España,  S.L.U.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
PALABRAS  CLAVE
Rotavirus;
Hacia  el  control  de  la  diarrea  por  rotavirus  A:  ¿podrían  los  nanoanticuerpos  VHH
marcar  la  diferencia?Diarreas  neonatales;
Resumen  Los  rotavirus  del  grupo  A  (RVA)  constituyen  la  principal  causa  de  diarrea  grave  y  mor-
ariable  de  los  anticuerpos  de  cadena  pesada  derivados  de  camélidos
idad  de  unión  antigénica  (reconocen  sitios  antigénicos  no  accesibles
les,  con  elevada  aﬁnidad)  tienen  bajos  costos  de  producción  y  resul-VHH;
Porción  variable  de
anticuerpos  de
cadena  pesada;
talidad infantil.  La  porción  v
presentan  una  amplia  capac
a los  anticuerpos  tradicionaNanoanticuerpos tan ideales  para  las  terapias  orales.  A  la  fecha,  se  desarrollaron  2  pares  de  nanoanticuerpos  VHH
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contra  RVA:  ARP1-ARP3  y  2KD1-3B2.  En  este  trabajo,  exploramos  el  potencial  de  ambos  grupos
de nanoanticuerpos  como  estrategias  de  prevención  complementarias  a  la  vacunación  y  como
una opción  de  tratamiento  frente  a  la  diarrea  asociada  a  RVA  en  poblaciones  de  riesgo.  Ambos
pares de  nanoanticuerpos  fueron  expresados  en  diferentes  sistemas  de  producción  y  mostraron
amplia capacidad  neutralizante  contra  diversas  cepas  de  RVA  in  vitro.  También  fueron  usados  en
el modelo  de  ratón  lactante,  en  el  que  evidenciaron  distintos  grados  de  éxito  en  la  prevención
o el  tratamiento  de  la  diarrea  inducida  por  RVA.  Es  interesante  destacar  que  la  mitigación  de
los síntomas  también  se  logró  con  ARP1  lioﬁlizado  y  conservado,  por  lo  que  podría  ser  utilizado
en áreas  donde  es  difícil  mantener  la  cadena  de  frío.  Asimismo,  3B2  fue  testeado  en  una  prueba
preclínica  utilizando  como  modelo  al  cerdo  gnotobiótico,  al  cual  conﬁrió  completa  protección
contra la  diarrea  inducida  por  RVA.  ARP1  fue  usado  en  la  primera  prueba  clínica  de  nanoanticuer-
pos VHH  contra  RVA,  donde  redujo  signiﬁcativamente  las  deposiciones  en  pacientes  pediátricos
con diarrea  positivos  para  RVA,  sin  evidenciar  ninguna  reacción  adversa.
© 2015  Asociación  Argentina  de  Microbiología.  Publicado  por  Elsevier  España,  S.L.U.  Este  es
un artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
a
u
h
t
o
s
v
T
T
s
d
r
t
d
a
c
Y
c
r
t
R
s
h
t
A
f
I
m
T
w
cIntroduction
Group  A  Rotavirus  (RVA)  is  the  main  source  of  severe
diarrhea  in  young  children,  accounting  for  approximately
453,000  deaths  every  year,  most  of  which  occur  in  devel-
oping  countries56.  Globally,  strains  of  four  G-P  combinations
are  responsible  for  about  90  %  of  all  RVA-associated  diar-
rhea  cases:  G1[P8],  G2[P4],  G3[P8]  and  G4[P8]46.  Although
a  similar  distribution  is  found  in  Latin  America,  G9[P8]  plays
an  important  epidemiological  role  in  this  region,  where  the
recent  emergence  of  G12  strains  has  also  been  reported13,33.
Prevention  of  RVA-associated  diarrhea:  where  do
we stand  today?
Two  vaccines,  a  single-strain  attenuated  human  RVA  (G1[P8])
vaccine  (ROTARIX,  GlaxoSmithKline  Biologicals),  and  a
multi-strain  bovine-human  reassortant  RVA  (G1-G4,  P1A)8
vaccine  (RotaTeq,  Merck),  are  available  and  have  shown
high  efﬁcacy  in  preventing  severe  RVA  gastroenteritis  in
industrialized14,43,63,64 and  some  developing  countries3,18,43.
However,  studies  show  that  RVA  vaccines  have  signiﬁcantly
lower  efﬁcacy  in  countries  with  limited  infrastructure  and
resources,  where  the  burden  of  RVA-associated  diarrhea  is
usually  highest34,71.  There  are  diverse  factors  that  affect
the  performance  of  oral  vaccines  in  impoverished  settings
including  nutritional  aspects  such  as  malnutrition  and  zinc
deﬁciency,  the  presence  of  competing  enteropathogens,
mucosal  alterations  in  the  gut  due  to  persistent  enteropa-
thy  and  high  levels  of  maternal  antibodies  (Abs)  in  breast
milk5.  Recently,  several  studies  have  determined  that
prenatal  vitamin  A  deﬁciency  alters  the  innate  immune
response  against  RVA  vaccination31,65.  Furthermore,  children
affected  by  severe  combined  immunodeﬁciency  have  suf-
fered  vaccine-acquired  RVA  infections  and  diarrhea40.Future  efforts  should  focus  on  optimizing  the  efﬁcacy,
safety,  accessibility  and  delivery  of  vaccines  among  high  risk
populations30 as  well  as  on  developing  new  passive  immu-
nization  strategies  that  could  serve  as  a  complement  or
(
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ulternative  to  vaccination.  Recently,  a new  oral  live  atten-
ated  RVA  (G9  P[11])  vaccine  (ROTAVAC)  developed  in  India
as  passed  clinical  phase  III9.  ROTAVAC  vaccine  is  cheaper
han  existing  vaccines  (1  USD  per  dose  versus  15  USD  for
ther  commercial  vaccines)  and  its  licensure  would  sub-
tantially  improve  the  access  of  developing  countries  to  RVA
accination9.
reatment  strategies  for  RVA-associated  diarrhea
reatment  strategies  against  RVA  are  non-speciﬁc  and  largely
ymptom-based.  Clinical  management  of  RVA-associated
iarrhea  is  based  on  preventing  dehydration  through  oral
ehydration  salts  (ORS)  administration,  zinc  supplemen-
ation,  and  continued  feeding68.  Several  attempts  to
evelop  a  speciﬁc  treatment  have  been  made,  including  the
dministration  of  RVA-speciﬁc  bovine  colostrum49,  mono-
lonal  Abs11 and  egg  yolk  polyclonal  immunoglobulin  (Ig)
Abs47,50,61, probiotics25,41,72, drugs42,45,57 and  natural  herbal
ompounds6,32.  Some  of  these  studies  showed  efﬁcacy  in
educing  diarrhea  duration  or  ﬂuid  loss,  but  none  of  these
reatments  was  adopted  as  a  standardized  procedure  against
VA-associated  diarrhea.  Additionally,  passive  immunization
trategies,  including  the  use  of  animal  colostrum  or  IgYAbs,
ave  raised  concern  about  possible  allergic  reactions  and
he  presence  of  adventitious  viruses.
 new  paradigm:  camelid  single-chain  antibody
ragments (VHHs)
n  1993,  Hamers-Casterman  et  al.27 discovered  an  IgG-like
aterial  in  the  serum  of  the  camel  (Camelius  dromedarius).
hese  molecules,  which  are  present  in  all  species  of  camelid,
ere  composed  of  heavy-chain  dimers  and  devoid  of  light
hains,  but  had  an  extensive  antigen-binding  repertoire27Fig.  1).  The  variable  domain  of  these  heavy  chain  anti-
odies,  known  as  VHH,  consists  of  only  one  polypeptide
hain  and  therefore  may  be  cloned  and  expressed  as  a  sol-
ble  protein  constituting  monoclonal  recombinant  antibody
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Figure  1  Schematic  representation  of  the  heavy  chains  antibodies  present  in  sera  of  the  camelids:  IgG2  and  IgG3.  Each  heavy
chain comprises  a  VHH,  a  hinge  region  and  two  constant  domains.  The  VHH  domain  includes  three  Complementary  Determining
Regions (CDRs)  which  are  depicted  as  colored  loops:  CDR1  red,  CDR2  green  and  CDR3  blue.  Adapted  from  Garaicochea  L,  Vega  CG,
Parren˜o V.  VHH  technology:  A  potential  passive  immune  therapy  to  control  Rotavirus  infections  in  human  infants.  In  Zeni  CD,  editor.
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ragments.  Because  of  their  reduced  size  (15  kDa)  and  the
rotruding  shape  of  the  paratope,  VHHs  display  potent
ntigen-binding  capacity  and  can  interact  with  novel  epi-
opes  inaccessible  to  conventional  Abs17,36,52.  VHHs  can  be
fﬁciently  produced  in  various  protein  expression  systems,
ncluding  Escherichia  coli23,  yeasts22,60,  insect  cells  and  lar-
ae  infected  with  baculovirus24,62,  and  transgenic  crops58.
hey  entail  low  costs  regarding  the  scaling  up  of  produc-
ion,  puriﬁcation  and  sterilization.  Moreover,  VHHs  show
xceptional  resistance  to  high  temperatures36 and  extreme
H19,28,  which  makes  them  ideal  candidates  for  developing
n  oral  prevention  strategy  and  a  viable  treatment  option
or  RVA-associated  diarrhea.  Although  nanobodies  are  sus-
eptible  to  degradation  by  pancreatic  enzymes  in  the  small
ntestine,  it  has  been  proved  that  the  co-administration
f  VHHs  with  milk  or  isolated  proteins  can  protect  them
rom  proteolytic  degradation  (unpublished  results).  The
mall  size,  stable  behavior,  rapid  clearance  from  blood,
nd  a  sequence  sharing  a  high  degree  of  identity  with  the
uman  VH  are  all  properties  that  predict  low  immuno-
enicity  of  a  nanobody36,  a  feature  that  is  highly  desirable
or  antibody-based  therapies.  Indeed,  no  immune  response
gainst  the  VHH  moiety  was  raised  in  mice  or  humans  paren-
erally  injected  with  nanobodies-containing  constructs  in
he  absence  of  adjuvants7,16.  In  the  case  of  oral  administra-
ion,  no  evidence  was  found  concerning  VHH  translocation
rom  the  intestinal  lumen  into  the  bloodstream62.
ingle-domain  antibody  fragments  (VHHs)  against
VA
o  the  best  of  our  knowledge,  two  sets  of  VHHs  against  RVA
ave  been  developed,  ARP1  (also  known  as  VHH1/2B10)  and
RP3,  both  comprising  the  ﬁrst  set2,60,  and  3B2  and  2KD1,
omprising  the  second  set23.  ARP1/3  were  isolated  from
n  adult  llama  immunized  with  rhesus-monkey  RVA  (RRV)
train  (G3P[3]I2)2,60 whereas  2KD1/3B2  were  obtained  from
n  adult  llama  previously  immunized  with  recombinant  VP6
t
t
c
ctment  options. 1st  edition.  New  York,  Nova  Publishers,  2014,
rotein  derived  from  the  bovine  RVA  C486  strain  (G6P[1])23.
oth  the  ARP1/ARP3  and  3B2/2KD1  sets  have  been  used  in
revious  studies  including  in  vitro  assays  (Table  1) and  pro-
ection/treatment  experiments  in  different  animal  models
Table  2).  ARP1  was  recently  tested  in  a clinical  trial  involv-
ng  infants  suffering  from  RVA  diarrhea  in  Bangladesh48.
n vitro studies
lones  ARP1  and  ARP3  successfully  neutralized  eleven  RVA
trains  (Table  1):  however,  they  surprisingly  failed  to  neu-
ralize  strains  SA11  (G3P[1])  and  RRV  (Kl  variant,  G3P[3]).
he  concentration  of  ARP1/ARP3  required  a  50  %  reduction
f  the  initial  dose  (100  FFU)  varied  between  strains  and
anged  from  0.63  g/ml  to  5.0  g/ml2. Meanwhile,  3B2  and
KD1  showed  neutralizing  activity  against  all  thirteen  strains
ested,  including  SA11  (G3P[1])  (Table  1).  In  this  case,  a
eduction  of  >80  %  of  the  virus  dose  (100  FFU)  was  achieved
ith  VHH  concentrations  ranging  from  15.63  g VHH/ml  for
A11  to  0.06  g  VHH/ml  for  Wa  and  F45  human  RVA  strains,
mong  others23,62 (Table  1).  On  the  whole,  both  sets  of
nti-RVA  VHHs  successfully  neutralized  different  RVA  strains,
lthough  2KD1/3B2  appeared  to  neutralize  a wider  range  of
trains  requiring,  overall,  lower  doses  of  VHH2,23.
Nevertheless,  the  precise  mechanism  involved  in  viral
eutralization  remains  unknown  for  both  sets  of  clones.
KD1/3B2  recognize  and  bind  speciﬁcally  to  the  VP6  protein,
s  they  were  obtained  from  a  llama  immunized  with  RVA
rotein  VP6.  For  ARP1  and  ARP3,  the  binding  site  was  uncer-
ain  as  the  llama  had  been  immunized  with  complete  virus
articles.  Recent  studies  indicated  that  ARP1  also  recog-
izes  and  binds  speciﬁcally  to  VP648. The  authors  further
mply  that  attachment  of  ARP1  to  VP6  might  trigger  a  con-
ormational  change  in  outer  layer  proteins  VP4  and/or  VP7,
hus  preventing  the  viral  particle  from  binding  to  or  entering
he  cells48.  Recent  studies  suggested  that  anti-RVA  IgA  Abs
ould  neutralize  viral  particles  by  attaching  to  a  negatively-
harged  patch  on  the  surface  of  Type  I  channel  and  sterically
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Table  1  In  vitro  neutralizing  capacity  of  ARP1/ARP3  and  2KD1/3B2  against  different  RVA  strains
by a  ﬂuorescent  focus  reduction  assay
g/ml  VHH  for  >50  %  reduction  of  100  FFU  g/ml  VHH  for  >80  %  reduction  of  100  FFU
RV strain  Genotype  ARP1/3a 3B2/2KD1b
Wa  G1P[8]  0.63  0.06
69M G8P[10]  0.63  0.98
F45 G9P[8]  0.63  0.06
DS1 G2P[4]  5.0  0.24
ST-3 G4P[4]  5.0  0.98
SA11 G3P[1]  NN  15.63
RRV (RIVM) G3P[3]  NN  ND
RRV (Kl) G3P[3]  NN  ND
Va70 G4P[8]  0.63  ND
WI61 G9P[8]  2.5  ND
RV4 G1P[8]  1.25  ND
M37 G2P[6]  1.25  ND
P G3P[8]  5.0  ND
H1 G5P[7]  ND  0.98
Gottfried  G4P[6]  ND  0.24
Arg720 G12P[9]  ND  3.91
C486 G6P[1]  ND  0.98
IND G6P[5]  ND  0.98
B223 G10P[11]  ND  0.98
H2 G3P[12]  ND  3.9
a Aladin et al. (2012)1.
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ND: not determined; NN: no neutralizing activity.
blocking  it1.  Further  experiments  should  assess  if  this  mech-
anism  could  also  be  used  by  nanobodies.
Prevention  and  treatment  of  RVA-induced  diarrhea
in neonatal  mice
Both  ARP1/ARP3  and  2KD1/3B2  were  tested  in  a  neona-
tal  mouse  model  for  protection  against  RVA-induced
diarrhea23,60.  The  neonatal  mouse  model  for  RVA  infection
was  developed  using  BALB/c  mice  in  early  studies  search-
ing  for  a  reliable  animal  model  mimicking  RVA  infection  in
human  patients10.  Mice  are  susceptible  to  murine  RVA  until
14  days  of  life  but  they  can  also  be  infected  with  some
other  RVA  strains.  However,  homologous  rotaviruses  (RV)
are,  in  general,  more  virulent  and  replicate  more  efﬁciently
than  heterologous  RV  in  the  intestine  of  the  homologous
host20.  Moreover,  RVA  host  restriction  was  proven  to  involve
a  multigenic  nature  in  which  efﬁcient  enteric  replication
requires  a  constellation  of  murine  genes  encoding  VP3,
NSP2,  and  NSP3  along  with  NSP120.  These  ﬁndings  cast  doubt
on  whether  the  neonatal  mouse  model  infected  with  het-
erologous  strains  could  be  used  in  pre-clinical  trials.  Groups
of  four-day  old  suckling  BALB/c  mice  received  different
clones  of  VHHs  orally,  prior  to  and  after  infection  with  a  mix-
ture  of  RRV  strain  and  a  VHH  previously  produced  in  yeast
(Saccharomyces  cerevisiae)60.  Of  these  clones,  however,
only  ARP1  was  successful  in  reducing  the  prevalence  of
RVA-induced  diarrhea  and  was  consequently  selected  for  fur-
ther  prophylactic  experiments.  Different  amounts  of  the
VHH  were  administered  to  four-day  old  mice  from  post
(
c
m
anoculation  days  −1  to  4.  On  day  0,  ARP1  was  delivered
wo  hours  after  infection  with  RRV  (2  ×  107 PFU).  While  low
aily  doses  (5  and  20  g)  of  the  nanobody  did  not  pro-
uce  signiﬁcant  differences  with  respect  to  the  non-treated
ontrol,  higher  amounts  of  the  VHH  (50  and  100  g)  success-
ully  reduced  the  number  of  days  with  diarrhea  per  pup60
Fig.  2A).
Later  on,  ARP1  and  ARP3,  previously  produced  in  yeast,
ere  tested  in  the  same  mouse  model  and  it  was  demon-
trated  that  ARP1  and  ARP3  target  different  epitopes  using
 competition  ELISA50.  If  administered  together,  this  combi-
ation  could  optimize  viral  neutralization  and  reduction  of
iral  escape  mutants.  When  tested  in  vivo, low  doses  of  ARP1
nd  ARP3  partially  protected  mice  infected  with  2  ×  107 FFU
f  RRV  strain  (20  diarrhea  doses  [DD50])  from  diarrhea.  The
ame  total  amount  (10  g)  of  the  mix  ARP1  +  ARP3  achieved  a
tronger  protection  than  ARP1  or  ARP3  alone,  especially  two
ays  after  inoculation  with  RVA  (RRV  strain);  however,  the
ifference  was  not  signiﬁcant.  This  could  imply  a synergistic
ffect  of  the  clones  that  needs  to  be  addressed.
Likewise,  prophylactic  experiments  involving  puriﬁed
KD1  and  3B2  produced  in  E.  coli  were  conducted23.
our  day  old  BALB/c  mice  received  a  daily  dose  (100  g,
2.2  mg/kg/day)  of  different  clones  of  VHH  from  days  post-
noculation  −1  to  4  via  intragastric  gavage.  On  PID  0,
ice  were  inoculated  with  either  bovine  RVA  (C486  strain,
6P[1])  containing  a  total  of  30  DD50  (6  ×  105 FFU/mouse)
experiment  A)  or  with  murine  RVA  (ECw  strain,  G16P[16])
ontaining  316  DD50  (experiment  B).  Two  hours  later  the
ice  received  the  daily  dose  of  VHH.  A  signiﬁcant  percent-
ge  (61  %)  of  mice  treated  with  3B2  and  infected  with  the
372
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Table  2  Preventive  and  therapeutic  strategies  against  Rotavirus-associated  diarrhea  using  VHHs  nanobodies
VHH  clone  RVA  strain  used  RVA  Genotype  Recombinant  protein
Expression  system  used
Strategy  Tested  on  Administration  Reference
ARP1  Rhesus  monkey  RVA
(RRV)
G3  P[3]  I2  Yeast  (Saccharomyces
cerevisiae)
Preventive  Neonatal  mice
(BALB/c)
Oral  van  der  Vaart  et  al.
(2006)60
ARP1  Rhesus  monkey  RVA
(RRV)
G3  P[3]  I2  Probiotics  (Lactobacillus
paracasei)
Preventive  Neonatal  mice
(BALB/c)
Oral  Pant  et  al.  (2006)38
ARP1,  ARP3  Rhesus  monkey  RVA
(RRV)
G3  P[3]  I2  Probiotics  (Lactobacillus
paracasei)
Preventive  and
‘‘therapeutic’’
Neonatal  mice
(BALB/c)
Oral  Pant  et  al.  (2011)39
ARP1  Rhesus  monkey  RVA
(RRV)
G3  P[3]  I2  Transgenic  rice  plants  Preventive  and
‘‘therapeutic’’
Neonatal  mice
(BALB/c)  and
adult  mice  (SCID)
Intragastrical,
in  rice  water
Tokuhara  et  al.
(2013)58
ARP1  (with
excipients)
Field  strains  G2  P[4],G9  P[8],
G1  P[8]
Yeast  (Saccharomyces
cerevisiae)
Randomized
placebo  control
ﬁeld  trial
(therapeutic)
Pediatric  patients  Oral,  with
orange  juice
Sarker  et  al.
(2013)48
3B2,  2KD1  Bovine  RVA  (C486
strain)
G6  P[1]  Escherichia  coli  Preventive  Neonatal  mice
(BALB/c)
Intragastrical  Garaicoechea  et  al.
(2008)23
3B2  Human  RVA  (Wa
strain)
G1  P[8]  I1  Baculovirus-infected
Insect  larvae
(Trichoplusia  ni)
Preventive  Gnotobiotic  pigs  Oral,  with  milk  Vega  et  al.  (2013)62
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Figure  2  Protection  rate  against  diarrhea  achieved  by  anti-
RVA nanobodies  in  neonatal  mice  challenged  with  various  RVA
strains.  Mouse  pups  were  fed  100  g  of  each  VHH  from  days  0  to
5 once  a  day  by  the  intragastric  route.  On  day  1,  the  pups  were
challenged  intragastrically  with  RVA  2  h  after  nanobody  admin-
istration.  Diarrhea  was  assessed  by  gentle  abdominal  palpation.
(A) Protection  rate  achieved  by  ARP1  in  mice  challenged  with
20 DD50  (2  ×  107 UFP)  of  rhesus  RV.  (B)  Protection  rate  achieved
by 2KD1  and  3B2  in  mice  challenged  with  30  DD50  (6  ×  105 FFU)
of bovine  RV  C486.  (C)  Protection  rate  achieved  by  2KD1  and
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In  2006,  Pant  et  al.38 constructed  Lactobacillus  paracasei3B2 in  mice  challenged  with  316  DD50  of  murine  RV  ECw.
bovine  RVA  strain  (Experiment  A)  were  protected  against
diarrhea  until  96  h  post  inoculation  (Fig.  2A),  at  which  point
they  were  euthanized23.  While  2KD1  was  not  capable  of  sig-
niﬁcantly  reduce  the  rate  of  diarrhea  at  that  time,  mice
treated  with  this  clone  signiﬁcantly  lowered  the  severity  and
duration  of  symptoms.  When  infected  with  the  murine  RVA
(Experiment  B),  similar  protection  rates  were  obtained  for
pups  treated  with  3B2  (60  %)  before  euthanasia  (Fig.  2B).
In  contrast,  all  pups  treated  with  2KD1  subsequently  devel-
oped  diarrhea,  although  there  was  a  delay  in  the  onset  of
symptoms  in  comparison  with  the  non-treated  control.  Mice
infected  with  ECw  murine  RVA  and  treated  with  3B2  signiﬁ-
cantly  reduced  viral  shedding  in  intestine  homogenates  at
t
a
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6  h  post  challenge.  The  2KD1-treated  groups  showed  no
etectable  shedding  by  ELISA  at  that  time23.
rotection  against  human  RVA  in  gnotobiotic  pigs
he  ability  of  3B2  to  prevent  the  occurrence  of  RVA-induced
iarrhea  was  also  tested  in  gnotobiotic  piglets62,  an  ani-
al  model  that  has  been  used  widely  to  study  human  RVA
athogenesis4,66,69,70.  In  this  case,  3B2  was  produced  using
he  Improved  Baculovirus  Expression  System  (IBES  Technol-
gy),  which  employs  baculovirus  expression  vectors  with
richoplusia  ni  larvae  as  living  biofactories24.  From  the  sec-
nd  day  of  life,  gnotobiotic  pigs  were  fed  commercial  bovine
ilk  supplemented  with  VHH  (ELISA  Ab  titer  to  RVA  of  4096,
.1  mg/ml  of  milk,  44  mg/pig/day  or  20--40  mg/kg/day)
wice  a  day  for  9  days.  On  day  3,  the  pigs  were  orally  inoc-
lated  with  106,7 UFF  of  human  RVA  (Wa  strain,  G1P[8]I1)
nd  were  daily  monitored  for  21  days  to  assess  the  occur-
ence  of  diarrhea  and  viral  shedding.  Serum  samples  were
ollected  weekly  and  were  used  to  study  immunological
arameters.  At  21  days  post  inoculation,  the  piglets  were
uthanized  and  their  intestines  were  collected.  Administra-
ion  of  3B2  conferred  complete  protection  against  human
VA-induced  diarrhea  in  all  treated  piglets62.  The  results
f  this  study  showed  higher  efﬁcacy  of  3B2  in  preventing
he  occurrence  of  diarrhea  than  previous  assays  using  this
ame  VHH  in  mice  models.  Although  viral  shedding  was
etected  in  the  3B2-treated  group,  excretion  duration  was
igniﬁcantly  lower  than  in  the  non-treated  groups.  Contin-
ed  administration  of  3B2  neither  affected  the  host  immune
esponse  to  RVA  infection  nor  elicited  an  immune  response
o  the  VHHs.  This  study  is  important  regarding  the  use  of
HHs  for  anti-RVA  therapy  in  small  infants62.  Although,  there
re  some  anatomic  differences  between  humans  and  pigs
egarding  the  gastrointestinal  tract,  neonatal  pigs  resem-
le  infants  in  several  ways.  Similar  to  infants,  they  are
mmunocompetent  at  birth,  but  immunologically  immature
nd,  as  outbred  animals,  they  are  closer  to  the  hetero-
eneity  of  human  populations35.  In  addition,  secretory  IgA
epresents  the  dominant  isotype  in  the  intestine,  milk  and
ucosal  secretions35. For  RVA  infection,  experimental  stud-
es  in  gnotobiotic  piglets  have  been  interpreted  to  indicate
hat  some  human  RV  strains  can  be  adapted  to  replicate
ery  efﬁciently  in  piglets,  although  a  comparison  to  wild-
ype  homologous  porcine  RV  replication  in  piglets  has  not
een  performed.  HRV-infected  gnotobiotic  pigs  exhibit  diar-
hea,  anorexia,  dehydration,  viremia  and  intestinal  lesions
imicking  those  in  children35.  As  the  study  was  focused  on
rophylactic  treatment,  further  research  should  analyze  the
fﬁcacy  of  3B2  when  administered  after  inoculation  or  after
he  initial  onset  of  diarrhea.
robiotics  expressing  VHHs
s  probiotics  have  been  employed  in  the  treatment  of  acute
iarrhea55,  their  combined  use  with  antiviral  VHHs  could
enerate  a synergistic  effect  against  RVA  gastroenteritis38.hat  expressed  the  anti-RVA  VHH  ARP1  in  secreted  and
nchored  forms.  Contrary  to  previous  in  vitro  assays,
his  time  ARP1  in  both  types  of  lactobacilli  was  able  to
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ecognize  and  neutralize  RVA  (RRV  strain)  particles  in  vitro.
or  the  secreted  form,  125  ng/ml  reduced  infectivity  by
0  %  whereas  for  the  anchored  form  1000  bacteria  (with
pproximately  1  ×  104 VHH  fragments/bacterium  equaling
pproximately  100  ng  VHH/ml)  were  necessary38.  Expression
f  VHHs  in  the  natural  gut  commensal  bacteria  surpasses
egradation  by  gastric  enzymes.  Effectively,  both  VHHs
ere  detected  in  the  jejunum  and  ileum  of  neonatal  mice
8  h  after  treatment  with  a  single  dose38.  The  transformed
actobacilli  were  tested  in  the  mouse  model  for  rhesus
VA  infection  (2  ×  107 FFU)  of  RRV  strain  (20  DD50)  as
escribed  previously60.  ARP1-anchored  lactobacilli  success-
ully  reduced  the  diarrhea  rate  in  comparison  to  untreated
ice  or  those  treated  with  irrelevant  VHHs.  In  addition,  this
reatment  signiﬁcantly  reduced  the  duration  and  severity
f  the  diarrhea  and  diminished  intestinal  inﬂammation  and
iral  load.  However,  the  ARP1-secreted  lactobacilli  group
nly  displayed  a  mild  reduction  of  the  symptoms,  probably
ecause  the  expression  levels  were  low.  Interestingly,
econstituted  freeze-dried  ARP1-anchored  lactobacilli  were
s  protective  against  diarrhea  as  their  fresh  counterparts38,
hich  is  important  regarding  clinical  administration  in
eveloping  areas  where  cold  chains  are  difﬁcult  to  maintain.
In  their  study  of  2011,  Pant  et  al.39,  administered  yeast
roduced  ARP1  and  ARP3  (previously  puriﬁed)  both  before
nd  after  inoculation  with  RRV  RVA.  When  the  mice  were
reated  two  hours  after  viral  inoculation,  10  g  of  ARP1  suc-
essfully  reduced  diarrhea  prevalence,  whereas  the  same
mount  of  ARP3  had  no  effect  on  the  symptoms.  Thus,  the
ombination  of  ARP1  +  ARP3  was  less  efﬁcient  than  when
t  was  administered  as  a  prophylactic  strategy35.  In  2011,
ant  et  al.39 went  further  and  developed  Lactobacillus
aracasei  that  displayed  anchored  ARP1  and  ARP3  on  their
urface  both  as  monospeciﬁc  or  bispeciﬁc  proteins:  ARP1,
RP3,  ARP1-ARP1,  ARP3-ARP3,  ARP1-ARP3.  As  ARP1  and
RP3  target  different  epitopes,  these  bispeciﬁc  constructs
ight  be  more  effective  in  preventing  the  selection  of  viral
scape  mutants  to  the  therapy,  a  concern  present  among
very  antiviral  strategy  based  on  monoclonal  Abs.  Monospe-
iﬁc  bivalent  ARP  compounds  (ARP1-ARP1,  ARP3-ARP3)  did
ot  show  increased  avidity  for  RVA,  perhaps  due  to  the  limi-
ation  of  effectively  binding  two  proximal  copies  of  the  same
pitope39.
Experiments  were  conducted  with  the  multimeric  VHH-
nchored  lactobacilli  in  the  neonatal  mouse  model  for
imian  RVA  infection  as  was  already  described,  using
 ×  107 FFU  of  RRV  strain  (20  DD50)  for  inoculation.  In  con-
rast  to  previous  results,  monovalent  anchored  ARP1  was
ble  to  signiﬁcantly  diminish  the  prevalence  and  severity  of
he  diarrhea  but  not  the  duration  of  the  symptoms  com-
ared  to  the  non-treated  control.  Anchored  monovalent
RP3  showed  a  similar  performance.  Bivalent  ARP3-ARP3-
nchored  lactobacilli  reduced  the  prevalence  and  severity
f  the  diarrhea;  however,  it  was  not  more  efﬁcient  that
he  monovalent  form  of  ARP3.  On  the  other  hand,  bivalent
nchored  ARP1  showed  poor  protection  against  RVA-induced
iarrhea  and  was  not  able  to  signiﬁcantly  reduce  disease
revalence  or  severity39.  Lactobacilli  expressing  bispe-
iﬁc  ARP1-ARP3  were  more  efﬁcient  in  decreasing  the
revalence  and  severity  of  the  diarrhea  with  respect  to
he  non-treated  control  and  also  in  comparison  to  the
ice  treated  with  monovalent  ARP1-producing  anchored
(
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actobacilli.  This  treatment  also  achieved  a signiﬁcant
eduction  in  diarrhea  duration,  which  was  not  observed  with
ny  of  the  other  treatments.
Interestingly,  a  mixture  of  lactobacilli  expressing  mono-
alent  ARP1  and  ARP3  was  only  marginally  protective  against
VA-induced  diarrhea,  suggesting  that  when  displayed  in
ifferent  bacterial  cells,  ARP1/ARP3  cannot  access  their
pitopes  simultaneously.  This  would  further  endorse  the
dea  that  the  increased  activity  encountered  for  lactobacilli
xpressing  ARP1-ARP3  is  due  to  initial  binding  of  ARP1  to  its
pitope,  thus  improving  the  targeting  of  a  transient  epitope
y  ARP339.
The  therapeutic  effect  of  ARP1  and  ARP3  anchored-
actobacilli  was  also  evaluated,  administering  the  nanobod-
es  two  hours  after  infection  and  then  daily.  Lactobacilli
xpressing  monovalent  ARP1  signiﬁcantly  reduced  the  sever-
ty  and  duration  of  diarrhea,  showing  higher  efﬁcacy  than
hen  administered  before  infection.  The  administration
f  ARP3-producing  bacteria  did  not  reduce  the  symptoms,
 result  congruent  with  previous  ones  for  yeast  puriﬁed
RP339. The  authors  explain  the  differential  performance
f  both  clones  by  suggesting  that  ARP3  could  only  attach
o  a more  concealed  epitope  if  present  during  early  stages
f  infection.  However,  it  is  also  possible  that  ARP3  is  less
ffective  than  ARP1  in  neutralizing  larger  amounts  of  viral
articles.  Lactobacilli  producing  ARP1-ARP1  showed  similar
esults  to  those  of  their  monovalent  form.  However,  the  bis-
eciﬁc  ARP1-ARP3  successfully  diminished  the  severity  and
uration  of  diarrhea,  showing  signiﬁcant  differences  with
he  non-treated  control  and  the  rest  of  the  treated  groups.
Viral  load  was  also  assessed  by  real  time  PCR  in  intesti-
al  tissue,  but  not  in  feces.  The  copy  numbers  of  the  VP7
ene  was  signiﬁcantly  reduced  only  in  mice  treated  prophy-
actically  with  lactobacilli  producing  monovalent  anchored
RP1  or  bispeciﬁc  anchored  ARP1-ARP3.  When  administered
fter  infection,  no  treatment  was  able  to  decrease  the  viral
oad39.
Overall,  probiotics  expressing  anti-RVA  VHHs  entail  sev-
ral  advantages  as  an  oral  therapy  in  large-scale  pediatric
opulations,  such  as  biological  safety,  increased  proteolytic
esistance,  and  retention  of  activity  after  being  freeze-dried
r  stored  for  long  periods  of  time.
ransgenic  crops  expressing  anti-RVA  VHHs
he  potential  of  plant  cells  to  produce  functional  recom-
inant  Abs  has  been  demonstrated  in  different  plant
ystems53. Previous  studies  reported  a  rice-based  vaccine
ontaining  the  cholera  toxin  B  subunit  effective  against
holera  in  mice37,58. More  recently,  the  same  system,  with
he  incorporation  of  RNAi  technology,  was  used  to  create
n  anti-RVA  product  by  concocting  rice  expressing  ARP1
MucoRice-ARP1)  which  could  be  used  as  rice  powder  or
ice  water58. RNAi  technology  was  used  to  suppress  the
nternal  storage  of  rice  protein  production  and  enhance
ccumulation  of  ARP1  instead58.  MucoRice-ARP1  successfully
eutralized  human  RVA  strains  of  different  serotypes  in  vitro
F45,  69M,  Va70,  Wa,  ST-3).  For  F45,  69M  and  Va70,  the  doses
ere  similar  to  those  of  yeast  puriﬁed  ARP1  (Table  1).  For
T-3  and  Wa  strains,  4  times  the  amount  of  MucoRice-ARP1
10  g/ml)  was  needed.
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When  it  was  tested  prophylactically  --  this  time  admin-
istering  the  ﬁrst  dose  nine  hours  prior  to  infection  --  in  the
mouse  model  for  RVV  infection,  17  g  of  MucoRice-ARP1  sig-
niﬁcantly  reduced  the  rate  of  mice  with  diarrhea  and  the
severity  of  the  symptoms  in  suckling  mice  infected  with
2  ×  107 FFU  of  RRV.  Mice  pre-treated  with  MucoRice-ARP1
did  not  present  histopathological  changes  in  the  small  intes-
tine  and  the  viral  load  in  that  tissue  was  signiﬁcantly  lower.
This  reduction  of  the  symptoms  and  of  virus  concentra-
tion  was  both  achieved  against  a  non-treated  control  and
against  a  group  of  mice  treated  with  wild  type  rice,  although
the  latter  showed  some  degree  of  improvement  due  to  the
astringent  properties  of  common  rice.  Interestingly,  no  sig-
niﬁcant  differences  were  found  between  fresh,  heat-treated
and  long-term  stored  Mucorice-ARP1  when  administered
prophylactically  to  mouse  pups58.
Furthermore,  Mucorice-ARP1  signiﬁcantly  reduced  the
rate  of  mice  with  diarrhea,  the  severity  of  symptoms  and
the  viral  load  in  a  neonatal  mouse  model  when  adminis-
tered  therapeutically  (17  g)  nine  hours  after  infection  with
RRV  RVA.  Interestingly,  MucoRice  powder  administered  the-
rapeutically  also  diminished  the  prevalence  and  severity  of
diarrhea  CB-17  SCID/SCID  neonatal  mice58,  which  could  rep-
resent  a  valid  model  for  studying  treatment  response  in
immunocompromised  infants.  For  what  they  called  a thera-
peutic  use  of  nanobodies,  the  authors  of  this  study  chose
to  administer  the  VHHs  nine  hours  after  infection.  How-
ever,  when  discussing  the  stability  of  MucoRice-ARP1  in  the
neonatal  mice  gut  they  report  that  in  up  to  40  %  of  the
mice,  MucoRice-ARP1  is  detected  even  9  h  after  intragas-
tric  administration58.  As  in  previous  studies  using  ARP1  in
the  neonatal  mouse  model,  this  latter  statement  contradicts
the  experimental  design  if  a  therapeutic  effect  of  the  VHHs
is  what  the  authors  seek  to  analyze.
Overall,  the  expression  of  VHHs  in  transgenic  crops  could
represent  an  attractive  strategy  to  generate  large  amounts
of  ready-to-use  nanobodies  utilizing  limited  resources.  In
contrast  to  previous  systems  such  as  tobacco  leaves,  the
use  of  comestible  seeds  implies  that  there  is  no  need
for  puriﬁcation.  Furthermore,  the  ﬁnal  product  was  a
highly  soluble  rice  powder  that  can  be  maintained  at
room  temperature  and  showed  high  stability  for  up  to
a  year  under  these  conditions58.  Since  the  primary  tar-
get  for  any  RVA  prevention  or  treatment  strategy  would
be  pediatric  populations  from  developing  countries,  high
stability  of  the  product  without  the  need  for  maintain-
ing  cold  chain  and  low  productions  costs,  all  represent
crucial  features  for  its  effective  implementation.  Given
that  groups  receiving  wild  type  rice  powder  showed  mild
improvement  in  relation  to  the  control  group  treated  with
PBS,  the  expression  of  anti-RVA  in  rice  has  the  additional
advantage  of  this  synergistic  effect  against  RVA-associated
diarrhea.
Treatment  against  RVA-associated  diarrhea  in
children from  Bangladesh:  a  randomized
placebo-controlled  trialRecently,  a  proof  of  concept  clinical  trial  was  performed
in  male  infants  with  RVA  infection  in  Bangladesh48.  The
design  of  the  study  implied  a  single  center,  randomized,
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ouble-blind,  placebo-controlled  parallel  group  clinical  trial
o  assess  the  efﬁcacy  of  ARP1  in  lowering  the  severity  and
uration  of  symptoms  compared  to  placebo,  in  male  children
resenting  acute  onset  dehydrating  diarrhea.
Brieﬂy,  176  male  children  aged  6--24  months  suffer-
ng  from  acute  watery  diarrhea  for  48  h  or  less  and  who
ested  positive  for  RVA  in  stool  by  ELISA,  but  negative  for
ibrio  cholerae,  were  randomly  assigned  to  the  ARP1  or
lacebo  group.  ARP1  was  produced  in  S.  cerevisiae  yeast
s  previously  described  and  the  treatment  dose  was  calcu-
ated  from  studies  in  the  neonatal  mouse  models60,  with
 maximum  daily  dose  of  35  mg/kg  of  ARP1  per  day.  The
anobody  was  administered  in  single  dose  sachets,  each  con-
aining  165  mg  of  the  yeast  preparation  expressing  35  %  of
RP1,  835  mg  maltodextrin  and  5  mg  caramel  color  (57.7  mg
RP1/sachet)  whereas  the  placebo  consisted  of  1000  mg
f  maltodextrin  with  5  mg  caramel  color.  Each  dose  was
uspended  in  10  ml  of  oral  rehydration  solution  and  adminis-
ered  orally,  starting  on  day  0  and  every  eight  hours  for  4--5
ays.  Frequency,  consistency  and  amount/volume  of  stool
ere  recorded  periodically  and  stool  consistency  scores
stablished  the  duration  of  symptoms.  Samples  of  fresh
tools  were  collected  daily  to  determine  the  presence  of
VA  by  ELISA  and  to  identify  the  RVA  serotype  (G  and  P
enotypes)  by  PCR;  RVA-speciﬁc  IgA  was  assessed  in  serum
amples.
When  only  RVA  infection  was  present,  the  total  cumula-
ive  stool  output  was  signiﬁcantly  lower  in  the  ARP1-treated
roups  compared  with  the  placebo  group,  showing  an  over-
ll  reduction  of  22.5  %48.  However,  when  other  concomitant
nfections  occurred,  there  were  no  signiﬁcant  differences
egarding  stool  output,  which  is  important  to  consider  as
VA-associated  diarrhea  can  often  present  with  other  infec-
ions,  mostly  of  bacterial  etiology.  ARP1  did  not  signiﬁcantly
educe  diarrhea  duration,  in  contrast  with  previous  stud-
es  in  mice60,  although  the  latter  were  mostly  based  on  a
reventive  use  of  ARP1.  No  differences  were  found  concern-
ng  viral  clearance  by  ELISA  between  treated  and  placebo
roups.  These  results  are  in  accordance  with  previous  data
rom  mice  experiments  wherein  administration  of  ARP1
id  not  reduce  viral  shedding,  even  when  administered
rior  to  infection60 and  in  contrast  with  mice  experiments
or  2KD1/3B2  where  the  RVA  shedding  signiﬁcantly  dimin-
shed  after  administration  of  the  2KD1/3B223. The  ARP1
nd  placebo  groups  showed  different  frequencies  of  RVA
erotypes,  although  statistical  analyses  indicated  that  this
nding  did  not  affect  the  trialoutcomel48. However,  because
revious  assays  showed  that  ARP1  had  a  different  neutral-
zation  capacity  against  different  strains  of  RVA2,  this  matter
hould  be  considered  more  thoroughly.
Although  the  results  of  the  ﬁrst  ﬁeld  trial  for  anti-RVA
HHs  are  promising,  there  is  still  room  for  improvement.
he  design  of  the  study  fails  to  account  for  the  effect  of
.  cerevisiae  against  RVA-associated  diarrhea  because  the
lacebo  group  only  received  colored  maltodextrin.  Numer-
us  previous  studies  have  addressed  the  use  of  another  yeast
pecies  and  its  effect  against  RVA-induced  diarrhea  with  dis-
imilar  results8,12,15.  Future  studies  comprising  the  use  of
RP1  as  an  oral  therapy  against  RVA  should  elucidate  the
ole  of  yeast  in  the  obtained  results,  given  that  previous
xperiments  in  the  neonatal  mouse  model  only  used  puriﬁed
HHs60.
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uture prospects
he  discovery  of  heavy-chain  antibodies  in  1993  was  a
roundbreaking  event  in  the  ﬁeld  of  immunology  and
ntibody-based  therapies.  In  particular,  llama-derived  single
omain  antibody  fragments  (VHHs)  have  proven  to  be  pow-
rful  viral  neutralizers21,51,60,62 and  have  been  studied  for
heir  therapeutic  use  against  respiratory  syncytial  virus29,
abies  virus29,  inﬂuenza  virus29,67 and  human  immunodeﬁ-
iency  virus21,54 among  others.  Up  to  date,  diarrhea  remains
 critical  health  issue  worldwide.  In  children  from  impover-
shed  areas,  the  recurrence  of  diarrhea  during  their  ﬁrst  2
ears  of  life  might  cause,  on  average,  an  8  cm  growth  short-
all  and  10  IQ  point  decrease  by  the  time  they  are  7--9  years
ld26.  The  use  of  VHHs  as  a  prevention  or  treatment  agent
gainst  RVA  offers  a  wide  range  of  possibilities  regarding  the
ontrol  of  RVA-associated  diarrhea  and  the  related  deaths  of
hildren  under  ﬁve  years  old.
Here,  we  have  surveyed  different  production  strategies
or  anti-RVA  VHHs:  E.  coli, yeasts,  insect  larvae  infected  with
aculovirus,  probiotics  and  transgenic  crops.  Regarding  the
atter,  we  believe  that  transgenic  crops  such  as  rice  plants
onstitute  a  highly  eligible  option.  Anti-RVA  VHHs  expressed
n  rice  plants  do  not  require  puriﬁcation  prior  to  adminis-
ration  and  they  entail  a  synergistic  effect  against  diarrhea
ue  to  the  astringent  properties  of  the  rice.  They  can  also
e  stored  at  room  temperature  for  months  without  compro-
ising  anti-viral  activity58,  which  represents  a  considerable
dvantage  for  the  administration  of  anti-RVA  VHHs  in  impov-
rished  areas  where  cold  chains  are  difﬁcult  to  maintain.
However,  we  have  previously  seen  that  stability  and  pro-
eolytic  resistance  of  3B2/2KD1  are  highly  increased  by  the
ddition  of  milk  (unpublished  results).  Moreover,  milk  is  dis-
ributed  by  governments  of  many  developing  countries  as
art  of  their  social  network  programs.  The  addition  of  anti-
VA  VHHs  to  milk  that  is  massively  delivered  in  high  risk
opulations  might  be  a  proﬁtable  and  successful  prevention
trategy  for  RVA  that  has  not  yet  been  implemented.  Given
he  previous  success  in  developing  transgenic  cattle  that
xpresses  various  molecules  of  therapeutic  interest  in  its
ilk44,59,  development  of  transgenic  cattle  expressing  anti-
VA  VHHs  within  mammary  glands  could  represent  another
ligible  strategy  for  VHH  production  that  excludes  the  need
f  thorough  puriﬁcation  techniques  otherwise  required  and
ould  entail  higher  social  acceptance  than  traditional  immu-
ization.  Regardless  of  which  production,  administration  or
linical  strategy  is  elected,  for  VHHs  to  succeed  as  standard-
zed  prophylaxis  and  treatment  strategy  against  RVA,  their
roduction  and  clinical  management  must  be  within  long-
erm  public  policies  allowing  impoverished  populations  to
ccess  higher  health  standards.
Clariﬁcation  of  the  molecular  interactions  that  mediate
he  neutralization  of  RVA  particles  by  VHH  clones  needs  to  be
ddressed  in  the  immediate  future.  A  complete  understand-
ng  of  the  molecular  mechanisms  involved  could  optimize
revention  and  therapeutic  uses  of  these  molecules.  Previ-
us  studies  with  either  set  of  clones  have  not  approached
he  possible  rise  of  viral  escape  mutants  to  anti-RVA  VHH,
hich  is  a  substantial  concern  for  any  antiviral  treatment
r  passive  immunization  strategy,  especially  in  the  case  of  a
ighly  transmissible  and  extensive  disease  such  as  RVA.L.  Maffey  et  al.
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